Managing Director, Klaipeda Health
David Memel, MD, MS, MBA, is the Managing Director of Klaipeda Health, a healthcare and life sciences advisory services company. David advises start-up, mid-size and global healthcare and life sciences organizations on product and service development, business model design, market development, commercialization strategies, product value demonstration and market access. David also serves as a Senior Fellow at the Healthcare Innovation and Technology Lab in New York City, an industry expert for Pacific Crest Securities’ Mosaic Group and a Business Strategy Advisor for the Castleton Group.
David has over 25 years of leadership, innovation and operating experience in multinational pharmaceutical, diagnostics, provider and payer organizations including Metabolon, Boehringer Ingelheim Pharmaceuticals, Aetna, Roche Diagnostics, Roche Pharmaceuticals and PeaceHealth. He has held a variety of commercial, clinical, scientific and analytics-focused informatics positions including Global and US Chief Medical Officer, Vice-President of Health Economics and Outcomes Research, Head of Informatics, Director of Medical Data Management and Analytics and Vice-President of Information Management and Quality.
David’s knowledge and experience in science, medicine, business and the strategic use of information enables him to bring an integrated perspective to identifying and seizing opportunities, solving complex challenges and delivering business value in the rapidly evolving world of value-based healthcare. In the course of his career, David has made significant contributions to development and commercialization of multiple pharmaceutical, diagnostic and analytics products and services. He also has built and led nearly a dozen healthcare and life sciences scientific, medical, informatics and commercial teams and organizations.
David began his career as a diagnostic and interventional radiologist. He received his B.S. and M.D. from the University of California at Los Angeles, his M.S. in medical informatics from the University of Utah, and a dual MBA from Cornell University and Queen’s University in Canada. David also completed a Fellowship in clinical effectiveness research at the Harvard School of Public Health.